C-reactive Protein & Albumin Ratio IN AKI

January 2, 2026 updated by: Noha Fathy Radwan Abd El Zaher, Assiut University

Correlation Between C-Reactive Protein to Albumin Ratio (CAR) and Acute Kidney Injury in Patients With Acute Pancreatitis in Assiut University Hospitals.

Acute pancreatitis (AP), defined as acute inflammation of the pancreas, it's one of the most common diseases of the gastrointestinal tract leading to hospital admission.(1) The global incidence of AP is reported between 20 and 40 cases per 100,000 individuals, with an increasing trend over recent decades. (2) Its severity ranges from mild self-limited disease to severe acute necrotizing pancreatitis characterized by systemic complications and multi-organ failure. AKI is a frequent complication of severe acute pancreatitis, usually after the failure of other organs. (3) The aetiology of AP can be readily established in most patients. The most common causes include gallstones (40%-70%) and alcohol (25%-35%), medications as 6-mercaptopurine and azathioprine clearly can cause AP, infectious agents, and metabolic causes such as hypercalcemia and hypertriglyceridemia are rare causes (4) Acute kidney injury (AKI), affects approximately 15% of AP patients increasing to 69% in severe AP cases. AKI not only worsens the clinical status of AP patients but also significantly increases mortality risk and the likelihood of progressing to chronic kidney disease (CKD. Therefore, the challenge of early AKI identification and timely therapeutic intervention in AP patients remains critical. (2) Albumin (ALB), a negative acute-phase reactant synthesized by the liver, constitutes 40% to 60% of total plasma protein and decreases during inflammation. (5) Serum CRP refers to a positive acute phase reactant synthesized by the liver and its level in the blood elevates within hours as a response to inflammation and infection and it can be applied in follow-up owing to the short half-life, easy measurement, as well as the close association with prognosis of the disease. (6) We aimed to assess the Correlation between C-Reactive Protein to Albumin Ratio (CAR) and Acute Kidney Injury (AKI) in Patients with Acute Pancreatitis (AP) as a cost-effective, easily accessible, and reproducible prognostic biomarkers for inflammation obtained from standard blood tests.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

patients with acute pancreatitis

Description

Inclusion Criteria:

  • 1)patients who were diagnosed with Acute Pancreatitis by the following criteria: (i) abdominal pain mostly referred to the back, (ii) serum amylase and/or lipase greater than 3 times the upper limit of normal, and/or (iii) diagnostic findings from imaging (CT abdomen). 2)patients over 18 years old.

Exclusion Criteria:

1) Pregnant or breastfeeding women 2)Length of hospital stay ≤ 24 h 3) Patients with CKD or end-stage renal disease. 4)patients with active malignancy. 5)patients with liver cirrhosis. 6)patients with active infections or surgeries

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
assessment of correlation between CRP/Alb ratio (CAR) and AKI in patients with acute pancreatitis (AP).
Time Frame: 10 days
10 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 30, 2026

Primary Completion (Estimated)

January 30, 2029

Study Completion (Estimated)

January 30, 2029

Study Registration Dates

First Submitted

January 2, 2026

First Submitted That Met QC Criteria

January 2, 2026

First Posted (Actual)

January 13, 2026

Study Record Updates

Last Update Posted (Actual)

January 13, 2026

Last Update Submitted That Met QC Criteria

January 2, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CRP and AKI

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Kidney Injuries

Clinical Trials on C-reactive protein to albumin ratio

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe